A 12 WEEK DOUBLE BLIND PLACEBO CONTROLLED STUDY OF GINKO BILOBA AUGMENTATION

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。研究银杏叶标准化提取物（Gb）是否可能是治疗精神分裂症症状，特别是阴性症状和/或改善其脑功能和记忆的有用的添加剂。本研究将采用双盲、随机、安慰剂对照设计，将纳入100例难治性精神分裂症受试者。受试者将随机接受标准剂量的Gb或安慰剂，持续12周，此外还将继续接受在进入研究前被判定为最佳的抗精神病药物治疗。标准评估工具将用于测量症状（阳性和阴性）、神经认知表现和功能状态的变化。将在基线以及第2、4、6和12周结束时进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To examine whether standardized estracts of Ginko biloba (Gb) might be a useful added agent in treating symptoms of schizophrenia, particularly negative symptoms and/or improve their brain function and memory. The study will use a double-blind, randomized, placebo-controlled design, and will include 100 subjects with treatment resistant schizophrenia. Subjects will be randomized to receive either a standard dose of Gb or placebo for 12 weeks in addition to continuing their treatment with anti psychotic medications that have been judged as optimal prior to entering the study. Standard assessment instruments will be used for measuring changes in symptoms (both positive and negative), neurocognitive performance and functioning status. Assessments will be done at baseline, and at the end of weeks 2,4,6 and 12.